Abstract

Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection in the Golden Syrian hamster causes lung pathology that resembles human coronavirus disease (COVID-19). However, extra-pulmonary pathologies associated with SARS-CoV-2 infection and post COVID sequelae remain to be understood. Here we show, using a hamster model, that the early phase of SARS-CoV-2 infection leads to an acute inflammatory response and lung pathologies, while the late phase of infection causes cardiovascular complications (CVC) characterized by ventricular wall thickening associated with increased ventricular mass/ body mass ratio and interstitial coronary fibrosis. Molecular profiling further substantiated our findings of CVC, as SARS-CoV-2-infected hamsters showed elevated levels of serum cardiac Troponin-I (cTnI), cholesterol, low-density lipoprotein and long-chain fatty acid triglycerides. Serum metabolomics profiling of SARS-CoV-2-infected hamsters identified N-acetylneuraminate, a functional metabolite found to be associated with CVC, as a metabolic marker was found to be common between SARS-CoV-2-infected hamsters and COVID-19 patients. Together, we propose hamsters as a suitable animal model to study post-COVID sequelae associated with CVC which could be extended to therapeutic interventions.

Data availability

All data pertaining to the manuscript are made available in Dryad.

The following data sets were generated

Article and author information

Author details

  1. Zaigham Abbas Rizvi

    Immuno-biology Lab, Infection and Immunology centre, Translational Health Science and Technology Institute, Faridabad, India
    For correspondence
    zaigham.abbas15@gmail.com
    Competing interests
    The authors declare that no competing interests exist.
  2. Rajdeep Dalal

    Immuno-biology Lab, Infection and Immunology centre, Translational Health Science and Technology Institute, Faridabad, India
    Competing interests
    The authors declare that no competing interests exist.
  3. Srikanth Sadhu

    Immuno-biology Lab, Infection and Immunology centre, Translational Health Science and Technology Institute, Faridabad, India
    Competing interests
    The authors declare that no competing interests exist.
  4. Akshay Binayke

    Immuno-biology Lab, Infection and Immunology centre, Translational Health Science and Technology Institute, Faridabad, India
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9808-9036
  5. Jyotsna Dandotiya

    Immuno-biology Lab, Infection and Immunology centre, Translational Health Science and Technology Institute, Faridabad, India
    Competing interests
    The authors declare that no competing interests exist.
  6. Yashwant Kumar

    Non-communicable disease centre, Translational Health Science and Technology Institute, Faridabad, India
    Competing interests
    The authors declare that no competing interests exist.
  7. Tripti Shrivastava

    Infection and Immunology centre, Translational Health Science and Technology Institute, Faridabad, India
    Competing interests
    The authors declare that no competing interests exist.
  8. Sonu Kumar Gupta

    Non-communicable disease centre, Translational Health Science and Technology Institute, Faridabad, India
    Competing interests
    The authors declare that no competing interests exist.
  9. Suruchi Aggarwal

    Non-communicable disease centre, Translational Health Science and Technology Institute, Faridabad, India
    Competing interests
    The authors declare that no competing interests exist.
  10. Manas Ranjan Tripathy

    Immuno-biology Lab, Infection and Immunology centre, Translational Health Science and Technology Institute, Faridabad, India
    Competing interests
    The authors declare that no competing interests exist.
  11. Deepak Kumar Rathore

    Infection and Immunology Center, Translational Health Science and Technology Institute, Faridabad, India
    Competing interests
    The authors declare that no competing interests exist.
  12. Amit Kumar Yadav

    Non-communicable disease center, Translational Health Science and Technology Institute, Faridabad, India
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9445-8156
  13. Guruprasad R Medigeshi

    Infection and Immunology Center, Translational Health Science and Technology Institute, Gurgaon, India
    Competing interests
    The authors declare that no competing interests exist.
  14. Amit Kumar Pandey

    Infection and Immunology Center, Translational Health Science and Technology Institute, Faridabad, India
    Competing interests
    The authors declare that no competing interests exist.
  15. Sweety Samal

    Infection and Immunology Center, Translational Health Science and Technology Institute, Faridabad, India
    Competing interests
    The authors declare that no competing interests exist.
  16. Shailendra Asthana

    Non-communicable disease centre, Translational Health Science and Technology Institute, Faridabad, India
    Competing interests
    The authors declare that no competing interests exist.
  17. Amit Awasthi

    Immuno-biology Lab, Infection and Immunology centre, Translational Health Science and Technology Institute, Faridabad, India
    For correspondence
    aawasthi@thsti.res.in
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2563-1971

Funding

THSTI core

  • Amit Awasthi

Translational Research Program

  • Amit Awasthi

DST-SERB

  • Amit Awasthi

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Shiv Pillai, Ragon Institute

Ethics

Animal experimentation: This study was performed in accordance with the institutional animal ethics committee (IAEC) guidelines and all the protocols and procedures involved in the study were approved (IAEC approval number: IAEC/THSTI/94). The experimental procedures on animals were followed in strict accordance with the animal handling and usage guidelines by the IAEC and small animal facility, THSTI. Infection through intranasal route was performed under anesthesia to minimize pain.

Human subjects: Human plasma samples were collected according to the recommended guidelines of the Institutional Ethics Committee (Human Research) of THSTI and ESIC Hospital, Faridabad (Letter Ref No: THS 1.8.1/ (97) dated 07th July 2020). Human blood samples were collected from COVID-19 patients and healthy individuals after the written informed consent. Individuals were enrolled in this study based on the inclusion/exclusion criteria prescribed by the Institutional Ethics Committee (Human Research) of THSTI.

Version history

  1. Preprint posted: January 11, 2021 (view preprint)
  2. Received: September 1, 2021
  3. Accepted: January 7, 2022
  4. Accepted Manuscript published: January 11, 2022 (version 1)
  5. Version of Record published: January 27, 2022 (version 2)
  6. Version of Record updated: January 31, 2022 (version 3)

Copyright

© 2022, Rizvi et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,405
    views
  • 478
    downloads
  • 40
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Zaigham Abbas Rizvi
  2. Rajdeep Dalal
  3. Srikanth Sadhu
  4. Akshay Binayke
  5. Jyotsna Dandotiya
  6. Yashwant Kumar
  7. Tripti Shrivastava
  8. Sonu Kumar Gupta
  9. Suruchi Aggarwal
  10. Manas Ranjan Tripathy
  11. Deepak Kumar Rathore
  12. Amit Kumar Yadav
  13. Guruprasad R Medigeshi
  14. Amit Kumar Pandey
  15. Sweety Samal
  16. Shailendra Asthana
  17. Amit Awasthi
(2022)
Golden Syrian hamster as a model to study cardiovascular complications associated with SARS-CoV-2 infection
eLife 11:e73522.
https://doi.org/10.7554/eLife.73522

Share this article

https://doi.org/10.7554/eLife.73522

Further reading

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Natalia E Ketaren, Fred D Mast ... John D Aitchison
    Research Advance

    To date, all major modes of monoclonal antibody therapy targeting SARS-CoV-2 have lost significant efficacy against the latest circulating variants. As SARS-CoV-2 omicron sublineages account for over 90% of COVID-19 infections, evasion of immune responses generated by vaccination or exposure to previous variants poses a significant challenge. A compelling new therapeutic strategy against SARS-CoV-2 is that of single-domain antibodies, termed nanobodies, which address certain limitations of monoclonal antibodies. Here, we demonstrate that our high-affinity nanobody repertoire, generated against wild-type SARS-CoV-2 spike protein (Mast et al., 2021), remains effective against variants of concern, including omicron BA.4/BA.5; a subset is predicted to counter resistance in emerging XBB and BQ.1.1 sublineages. Furthermore, we reveal the synergistic potential of nanobody cocktails in neutralizing emerging variants. Our study highlights the power of nanobody technology as a versatile therapeutic and diagnostic tool to combat rapidly evolving infectious diseases such as SARS-CoV-2.

    1. Microbiology and Infectious Disease
    Michael D Sacco, Lauren R Hammond ... Yu Chen
    Research Article Updated

    In the Firmicutes phylum, GpsB is a membrane associated protein that coordinates peptidoglycan synthesis with cell growth and division. Although GpsB has been studied in several bacteria, the structure, function, and interactome of Staphylococcus aureus GpsB is largely uncharacterized. To address this knowledge gap, we solved the crystal structure of the N-terminal domain of S. aureus GpsB, which adopts an atypical, asymmetric dimer, and demonstrates major conformational flexibility that can be mapped to a hinge region formed by a three-residue insertion exclusive to Staphylococci. When this three-residue insertion is excised, its thermal stability increases, and the mutant no longer produces a previously reported lethal phenotype when overexpressed in Bacillus subtilis. In S. aureus, we show that these hinge mutants are less functional and speculate that the conformational flexibility imparted by the hinge region may serve as a dynamic switch to fine-tune the function of the GpsB complex and/or to promote interaction with its various partners. Furthermore, we provide the first biochemical, biophysical, and crystallographic evidence that the N-terminal domain of GpsB binds not only PBP4, but also FtsZ, through a conserved recognition motif located on their C-termini, thus coupling peptidoglycan synthesis to cell division. Taken together, the unique structure of S. aureus GpsB and its direct interaction with FtsZ/PBP4 provide deeper insight into the central role of GpsB in S. aureus cell division.